PubMed

Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration.

Schmidt-Erfurth U, Wolf S; PROTECT Study Group.

Br J Ophthalmol. 2008 Dec;92(12):1628-35. Epub 2008 Sep 4.PMID: 18772178 [PubMed - indexed for MEDLINE]Related articles

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Verteporfin In Photodynamic Therapy Study Group.

Am J Ophthalmol. 2001 May;131(5):541-60.PMID: 11336929 [PubMed - indexed for MEDLINE]Related articles

Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study.

Kiss CG, Simader C, Michels S, Schmidt-Erfurth U.

Br J Ophthalmol. 2008 Dec;92(12):1620-7.PMID: 19029163 [PubMed - indexed for MEDLINE]Related articles

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

[No authors listed]

Arch Ophthalmol. 1999 Oct;117(10):1329-45. Erratum in: Arch Ophthalmol 2000 Apr;118(4):488. PMID: 10532441 [PubMed - indexed for MEDLINE]Related articles

[Intravitreal ranibizumab in combination with verteporfin photodynamic therapy in neovascular macular degeneration]

Soucek P, Soucková I.

Cesk Slov Oftalmol. 2008 Jul;64(4):135-40. Czech. PMID: 18780651 [PubMed - indexed for MEDLINE]Related articles

Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.

Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J, Potter MJ, Reaves A, Rosenfeld PJ, Slakter JS, Soucek P, Strong HA, Wenkstern A, Su XY, Yang YC; Visudyne in Minimally Classic Choroidal Neovascularization Study Group.

Arch Ophthalmol. 2005 Apr;123(4):448-57.PMID: 15824216 [PubMed - indexed for MEDLINE]Related articles

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY; FOCUS Study Group.

Arch Ophthalmol. 2006 Nov;124(11):1532-42. Erratum in: Arch Ophthalmol. 2007 Jan;125(1):138. PMID: 17101999 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.

Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE.

Am J Ophthalmol. 2009 May;147(5):831-7. Epub 2009 Feb 13.PMID: 19217019 [PubMed - indexed for MEDLINE]Related articles

Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.

Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.

Arch Ophthalmol. 2002 Nov;120(11):1443-54.PMID: 12427056 [PubMed - indexed for MEDLINE]Related articles

Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.

Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas ES.

Arch Ophthalmol. 1999 Sep;117(9):1161-73. Erratum in: Arch Ophthalmol 2000 Apr;118(4):488. PMID: 10496388 [PubMed - indexed for MEDLINE]Related articles

Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.

Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM.

Arch Ophthalmol. 1999 Sep;117(9):1177-87. Erratum in: Arch Ophthalmol 2000 Apr;118(4):488. PMID: 10496389 [PubMed - indexed for MEDLINE]Related articles

Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).

Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU.

Graefes Arch Clin Exp Ophthalmol. 2007 Sep;245(9):1273-80. Epub 2007 Feb 28.PMID: 17333238 [PubMed - indexed for MEDLINE]Related articles

Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.

Kourlas H, Abrams P.

Clin Ther. 2007 Sep;29(9):1850-61. Review.PMID: 18035187 [PubMed - indexed for MEDLINE]Related articles

Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Japanese Age-Related Macular Degeneration Tial (JAT) Study Group.

Am J Ophthalmol. 2003 Dec;136(6):1049-61.PMID: 14644215 [PubMed - indexed for MEDLINE]Related articles

Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients.

Bessler NM; Vam Study Writing Committee.

Retina. 2004 Aug;24(4):512-20. Erratum in: Retina. 2004 Dec;24(6):990. PMID: 15300071 [PubMed - indexed for MEDLINE]Related articles

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group.

N Engl J Med. 2006 Oct 5;355(14):1432-44.PMID: 17021319 [PubMed - indexed for MEDLINE]Related articlesFree article

Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.

Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Monés JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.

Arch Ophthalmol. 2002 Oct;120(10):1307-14.PMID: 12365909 [PubMed - indexed for MEDLINE]Related articles

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.

Arch Ophthalmol. 2001 Feb;119(2):198-207.PMID: 11176980 [PubMed - indexed for MEDLINE]Related articles

Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.

Lazic R, Gabric N.

Ophthalmology. 2007 Jun;114(6):1179-85.PMID: 17544776 [PubMed - indexed for MEDLINE]Related articles

Randomized multicenter trial of more intense and standard early verteporfin treatment of neovascular age-related macular degeneration.

Schmidt-Erfurth U, Sacu S; Early Retreatment Study Group.

Ophthalmology. 2008 Jan;115(1):134-40.PMID: 18166408 [PubMed - indexed for MEDLINE]Related articles